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While the ability to detect PCa has improved significantly due to PSA screenings, the survival 
rate for men diagnosed with PCa has remained stagnant, and the disease remains the second leading 
cause of cancer related deaths in men. Most patients initially respond to androgen deprivation 
treatment; however, a significant percentage of patients relapse with currently untreatable castration 
resistant prostate cancer (CRPC), during which the PCa cells develop the ability to grow in androgen 
depleted conditions. The androgen receptor (AR) plays a vital role in prostate development and 
homeostasis, and the deregulation of AR drives PCa tumorigenesis and progression to CRPC. Delineating 
molecular mechanisms that contribute to AR activity and/or PCa cell growth in androgen-depleted 
conditions may aid in the development of future CRPC therapies 
Epigenetic alterations play a critical role in differentiation during development, and aberrations 
in epigenetic regulation are associated with tumorigenesis and cancer progression. Two types of 
epigenetic modifications, DNA methylation and the methylation of multiple histone lysines, play 
significant roles in prostate cancer (PCa). Many histone methyltransferases (HMT) and demethylases 
(HDM), including the JMJD2 family of histone demethyalses, act as coregulators of AR, and many of 
these enzymes are implicated in CRPC. Because of this, HDMSs and HMTs have proven as attractive 
targets for therapeutic intervention.  
  
We have been studying TMEFF2, a protein that is regulated transcriptionally and translationally 
by the AR, and is overexpressed in PCa and CRPC suggesting a role in this disease. Data presented here 
demonstrate that TMEFF2 modulates JMJD2 controlled methyl histone marks and increases growth in 
androgen depleted conditions in CRPC cells. In correlation with its effect on histone methylation and 
growth, TMEFF2 overexpression increases resistance to the anti-growth effects of the pan-jumonji 
demethylase inhibitor, JIB-04, suggesting that TMEFF2 modulates growth, at least in part, by increasing 
jumonji demethylase activity. Additionally, TMEFF2 positively regulates PSA expression without altering 
AR levels in CRPC cells, indicating that TMEFF2 is a novel activator of AR. All together this data suggests a 
model in which TMEFF2, by modulating the activity of AR and JMJD2 enzymes, increases CRPC cell 
growth. Because CRPC remains to be a significant obstacle in the successful treatment of metastatic PCa, 
the results presented have the potential to be of therapeutic value.    
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Chapter 1: Introduction 
 
Epigenetics Overview 
 During mitosis, the parental cell’s DNA is replicated in a precise process with high fidelity and 
limited error. Because every cell that makes up an organism is a result of repeated cell division that can 
be traced back to a single cell, each cell has an almost identical genome, and variances that occur in DNA 
base sequence within an individual’s lifetime are only a result of error during DNA replication. Despite 
having the same genome, different cell types have drastically different phenotypes and carry out 
different functions that contribute to a physiologically functional organism. The phenotype and function 
of a specific cell type is determined by the genes that are expressed, and it is therefore vital that cells 
maintain gene expression signatures through cell division. In a sense, a cell must have “memory” of its 
specific cell type. During development, pluripotent embryonic stem cells (ESCs) differentiate and commit 
to specific cell lineages and eventually, after multiple cycles of growth and differentiation, give rise to all 
of the different cell types that make up an organism. The process of differentiation is accompanied by 
alterations in gene expression in a manner that is lineage specific, and the newly acquired gene 
expression signature of the differentiated cell must be maintained through cell division or until the cell 
differentiates once again. Many of the mechanisms that contribute to cellular memory and gene 
expression changes during development are regulated by differential packaging of the DNA in the 
nucleus.  
 Each human cell contains approximately two meters of DNA, which is tightly packed into a 
nucleus with a diameter of roughly five to ten micrometers (1). To solve this spatial problem, DNA is 
both highly organized and tightly packaged in the form of chromatin.  The primary structure of 
chromatin involves the interaction between the DNA and core histone proteins (1). The four core 
histone proteins (H2A, H2B, H3, and H4) form an octameric complex, which includes two of each 
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(1).Because of their high arginine and lysine content, histone proteins carry a positive charge, which 
gives the octameric histone complex a high affinity for negatively charged DNA. The DNA is wrapped 
around the core histone octameric complex to form a nucleosome, the primary structure of chromatin. 
Nucleosomes are connected by what is called linker DNA, and are further packaged to form more 
complex structures, such as chromatin fibers, and other chromatin-associated proteins and remodeling 
factors aid in the dynamics of the packaging process. The majority of a cell’s DNA does not contain 
genes; therefore these sections of the genome are tightly packed in a form of chromatin called 
constitutive heterochromatin (2). Regions of the chromatin that contain genes are called euchromatin, 
and in these regions chromatin compaction must be a dynamic process. In regions of actively 
transcribed genes, the euchromatin forms an open structure which allows for transcription factor 
access; while euchromatic regions of transcriptionally repressed genes are tightly condensed into 
facultative heterochromatin, which resembles constitutive heterochromatin in structure (2). In this 
manner, the dynamic capacity of euchromatin structure controls gene transcription by affecting 
transcription factor and RNA polymerase accessibility to promoter and enhancer elements. The 
mechanisms that regulate gene expression via chromatin structure modulation are studied in a field 
called epigenetics.    
 Epigenetics is the study of heritable alterations in phenotype and/or gene expression that are 
not a result of changes in DNA base sequence. DNA methylation and histone post-translational 
modifications are two main mechanisms of epigenetic regulation, and will be briefly discussed below. 
Both modifications contribute to chromatin-remodeling and chromatin condensation and/or 
decondensation; therefore, both modifications can influence gene expression. Importantly, the 
regulated organization of chromatin is inherited through cell division via epigenetic mechanisms; for this 
reason, epigenetic regulation provides mechanisms through which the cell can transmit a blueprint for 
its cell type-specific gene expression signature to future cell generations (3,4,5). Not only does 
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epigenetic regulation contribute to the rigidity of cell memory, but it also has plasticity, which provides a 
cell with a certain level of adaptability to alter gene expression in response to environmental stimuli, 
and during differentiation in development (5).The relevance of epigenetic mechanisms in regulating 
cellular homeostasis is underscored by the fact that epigenetic aberrations have been linked to many 
different disease states, such as, cancer, diabetes, and Alzheimer’s (6,7,8).  
 DNA methylation occurs on cytosine nucleotides which are located next to a guanine nucleotide 
on the 3’ end. These motifs are called CpG sites. Interestingly, CpG sites are globally under-represented 
across the genome when compared to other dinucleotides (9,10). This under-representation is thought 
to be a result of spontaneous deamination events that occur on methylcytosines, which results in a 
conversion of the methylcytosine to thymine, or a C to T transition. However, clusters of CpG sites, or 
CpG islands, occur within the promoter regions of roughly 60% of the genes across the genome (11), and 
the methylation of these CpG sites can influence the expression of associated genes by 1) acting as a 
steric block for transcription factor binding (12,13,14), 2) recruiting chromatin remodeling factors that 
can then condense the chromatin in regions proximal to gene promoters (15,16). CpG methylation is 
catalyzed by the DNA methyltransferases DNMT1, DNMT3a and DNMT3b. DNMT1 is a maintenance 
methyltransferase, in that it only has the ability to methylate hemi-methylated DNA, and primarily 
functions to maintain DNA methylation patterns through cell division(17); while DNMT3a and DNMT3b 
are both de novo methyltransferases (17,18). Although DNA methylation is a stable mark, it is reversible 
via a hydroxylation reaction catalyzed by the TET family of DNA demethylases (19). Both DNMT’s and 
TET demethylases are involved in development and are dysregulated in many cancers, and 
hypomethylating agents, azacitidine and decitabine, are FDA approved drugs for treating 
myelodysplastic syndromes (20). 
Core histones are globular proteins that have terminal peptide tails that radiate out from the 
central nucleosome (21). These histone tails contain multiple amino acids which serve as sites for a 
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multitude of post-translational modifications (PTMs), including methylation, acetylation, 
phosphorylation, ubiquitynation, and sumoylation (22). Both lysine acetylation and methylation are 
prominent gene expression regulatory mechanisms, and will be discussed further.  
 Histone lysine acetylation is by catalyzed histone acetyltransferases (HATs) (23). Upon the 
addition of the acetyl mark, the positive charge of the lysine is neutralized. It is hypothesized that this 
loss of charge reduces the affinity of the histone tail for the DNA, and thus contributes to chromatin 
decondensation. In support of this hypothesis, it has been long understood that acetyl lysine marks 
occur near the promoter regions of actively transcribed genes (22,24). Histone deacetylation is carried 
out by histone deacetylases (HDACs) (25). Because the removal of the acetyl group restores the positive 
charge on the lysine, HDACs act as transcriptional repressors (25).Multiple HDAC enzymes have been 
found to be overexpressed in a variety of cancers, and there are currently two FDA approved HDAC 
inhibitors for cancer therapy, vorinostat and depsipetide (26). 
 Histone lysine methylation is catalyzed by histone methyltransferases (HMTs) (27). Unlike 
acetylation, methylation does not alter the charge of the lysine. Histone lysine residues can be 
monomethylated (me1), dimethylated (me2), or trimethylated (me3), and depending on the target 
lysine, the degree of methylation can have a differential impact on gene expression (28,29). Most of the 
currently understood histone methyl marks occur on H3 and H4. Of the trimethylated lysine marks, 
histone 3 lysine 9 trimethylation (H3K9me3), H3K27me3, and H4K20me3 are usually transcriptionally 
repressive marks, while H3K4me3, H3K36me3, and H3K79me3 are usually transcriptionally active marks 
(29). Although the charge of lysine is not affected by the methylation state, there is evidence that 
methyl histone marks may act as targets for reader proteins, which bind to the methyl histone mark and 
contribute to the modulation of the chromatin state (30). Multiple protein domains have been found to 
have histone methyl lysine binding capabilities, including, PHD fingers, chromodomains and tudor 
domains (30). Heterchromatin protein 1 (HP1) is a well characterized example of a histone reader 
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protein that modulates chromatin structure. HP1 binds to H3K9me3 via its chromodomain, and this 
recognition has been shown to be critical for heterochromatin formation and contributes to DNA 
methylation (31,32). 
 Histone methyl lysines are demethylated in a reaction catalyzed by two classes of histone 
demethylases (HDMs), the Jumonji C (JMJC)- domain containing family and the LSD family (33). The LSD 
family utilizes a FAD-dependent oxidase reaction mechanism, during which FAD acts as an oxidizing 
agent and the target methyl group is released in the form of formaldehyde in the presence of oxygen 
(34). Because the LSD family reaction mechanism requires a free electron pair on the nitrogen of the 
target lysine, LSD enzymes are only capable of demethylating me1 or me2 lysines (33). The JMJC-domain 
containing, or jumonji demethylases, are characterized by a C-terminal jumonji domain, which contains 
the catalytic center for these enzymes (35). The jumonji demethylases utilize iron and α-ketoglutarate as 
cofactors. In the presence of oxygen, the jumonji demethylases hydroxylate the target methyl group, 
which then results in the spontaneous release of formaldehyde (36,37). The jumonji demethylases can 
theoretically demethylate me3, me2 or me1 lysine residues; however, each jumonji demethylase may 
have preferential activity towards a particular level of methylation (33). 
Because histone methylation can activate or repress transcription depending on the target 
lysine and degree of methylation, HMTs and HDMs can act as either transcriptional activators or 
repressors in a manner that is dependent on their catalytic activity. Importantly, HMTs and HDMs have 
been shown to play key roles in gene expression regulation during development, and aberrations in their 
expression and/or activity have been observed in many different cancer types (12,33).   
 
 
 
 
  
One Carbon Metabolism and its Role in Epigenetic Regulation 
One carbon metabolism can be separated into three separate cycles or shunts: the folate cycle, 
the methionine cycle, and the transsulfuration pathway (see figure 1 for one carbon metabolism 
schematic). The folate cycle contributes to pyrimidine and purine synthesis, as well as methionine 
regeneration in the methionine cycle. Methyl THF is a cofactor for methionine synthase, which catalyzes 
the methyl transfer from methyl THF to homocysteine to form methionine. Methionine is then 
converted to S-adenosylmethionine (SAM) in an ATP-dependent reaction catalyzed by methionine 
adenosine transferase. SAM is the universal methyl donor for methyltranserase reactions involved in 
DNA methylation, histone methylation, as well as the methylation of other proteins. Upon donating a 
methyl group in methyltransferase reactions, SAM is converted to S-adenosylhomocysteine (SAH), which 
is then converted back to homocysteine in a reaction catalyzed by SAH hydrolase. Because SAM is 
required as a methyl donor in DNMT and HMT reactions, alterations in one carbon metabolism flux can 
influence epigenetic modifications and therefore the expression of genes regulated by DNA and/or 
histone methylation (38). One example that provides evidence that epigenetic alterations can be caused 
by disruptions in one carbon metabolism is seen in studies conducted with methylene tetrahydrofolate 
reductase (MTHFR) deficient mice. MTHFR is an enzyme within the folate cycle that catalyzes the 
formation of methyl THF from methylene THF. Offspring of MTHFR deficient/wild type crosses inherit 
epigenetic alterations that result in developmental disorders that are inherited through multiple 
generations (39). 
Homocystiene can also be converted into cystathionine in a reaction catalyzed by cystathionine 
β synthase (CBS), and this reaction is the first and committed step of the transsulfuration shunt of one 
carbon metabolism. The transsulfuration pathway is responsible for the synthesis of glutathione, a 
required metabolite for glutathione peroxidase and glutathione transferase enzymes, which are 
responsible for radical oxygen species (ROS) and toxin neutralization, respectively (40). It has been 
 demonstrated that increases in ROS can contribute to HIF
site of HIF-1α specific prolyl hydroxylases, thereby inhibiting their activity 
increases in ROS have been demonstrated to contribute to histone hypermethylation
that ROS can also inhibit jumonji histone demethylases, which are also iron dependent hydroxylases
Therefore, changes in one carbon flux that influence entrance into t
alter the activity of histone demethylases; however, the net effect of ROS on demethylation is 
complicated, as HIF-1α, which is stabilized by increases in ROS,
hydroxylases, including many of the jumonji demethylases (
be a compensatory mechanism, so that, when iron
in ROS or decreases in oxygen, the expression of thes
shown that methyl cytosines are sensitive to hydroxylation caused by hydroxyl radicals, which can lead 
to a loss in DNA methylation (44). Therefore, although mechanistically complicated, fluxes in one carbon 
metabolism can influence epigenetic regulation by altering methylation and demethylation reactions.
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Epigenetics in Cancer 
 Cancer has long been only considered a disease of the genome, during which, mutations in the 
DNA base sequence occur within tumor suppressor genes and oncogenes that drive the transformation 
of normal cells into cancer cells. Two different types of mutations occur during cancer development, loss 
of function and gain of function mutations. Loss of function mutations occur within tumor suppressor 
genes and lead to the suppressed function of the coded proteins. Tumor suppressor genes include 
proteins that apply brakes to the cell cycle, suppress invasion, contribute to apoptosis, participate in 
DNA repair, and control cell metabolism. Conversely, gain of function mutations occur within oncogenes 
and contribute to the aberrant activation of the coded proteins which promote tumor growth and 
development. During oncogenesis and cancer progression, genetic mutations continue to accumulate, 
and mutations that contribute to a growth advantage are naturally selected for through cell division as 
the tumor grows and evolves. While considering cancer a disease of the genome is accurate, this 
definition of cancer is incomplete at best; cancer should also be defined as a disease of the epigenome. 
Epigenetic aberrations in cancer lead to decreased expression of tumor suppressor genes and increased 
expression of proto-oncogenes during tumorigenesis and cancer progression (12). Because epigenetic 
modifications, such as DNA methylation and histone PTM’s, are inherited through cell division, 
epigenetic alterations that contribute to a selective growth advantage are transmitted to future 
generations of cancer cells through clonal expansion.  
Aberrant DNA methylation is a common occurrence in cancer. Both promoter specific 
hypermethylation and global hypomethylation are prevalent epigenetic characteristics of cancer cells 
(45). In cancer cells, promoter specific hypermethylation often occurs at tumor suppressor genes, which 
represses their expression. The tumor suppressor, Rb, was the first gene found to be silenced via DNA 
hypermethylation in cancer (46). Since that finding, a multitude of tumor suppressor genes, including, 
BRCA1, p16, PTEN, GSTP1, and MGMT, have been discovered to be hypermethylated in many cancers 
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(47-50).  All three DNMTs have been found to be over-expressed in many different cancer types, which 
may contribute to promoter hypermethylation and gene silencing (51,52,53).Finally, HDAC enzymes are 
also overexpressed in cancer and contribute to DNA-methylation induced gene silencing in cancer cells 
(54). Through their interaction with CpG binding proteins, HDACs are recruited to hypermethylated 
promoters, where they further repress transcription by deacetylating proximal histones (15,16).   
Global hypomethylation involves losses of DNA methylation at repetitive sequences, which can 
lead to transposable element activation, and increased genomic and chromosomal instability (55,56). 
This instability can contribute to an increased mutation rate and chromosomal aberrations, such as, 
deletions and translocations in cancer cells. Hypomethylation occurring at the promoter of oncogenes 
can also result in aberrant increases in oncogene expression (57,58,59). The causation of genomic 
hypomethylation is probably multi-factorial, and has yet to be delineated. One intriguing correlation 
links one carbon metabolism to DNA hypomethylation and cancer risk. Although somewhat 
controversial, multiple studies have found that decreased folate intake, which is an important cofactor 
for one carbon transfer reactions in one carbon metabolism, correlates with DNA hypomethylation and 
increased cancer risk, especially in colon cancer (60,61,62). Because folate plays a key role in the 
methionine cycle and S-adenosylmethionine (SAM) regeneration, which is the universal methyl donor 
for methyltransferase reactions, it is possible that folate deficiency may have a causational role in the 
development of global hypomethylation in some cancers. Furthermore, polymorphisms in MTHFR, 
which reduce its activity, correlate with increased cancer risk in a number of cancers, and this risk may 
be exacerbated by low dietary folate intake (63,64).   
Histone methylation also plays an important role in cancer development and progression. 
Multiple cancer types have been found to exhibit a multitude of aberrations in histone methylation, and 
many HMTs and HDMs have altered expression in cancer cells in comparison to non-transformed cells 
(65). By acting as transcriptional activators and repressors, HMTs and HDMs alter the gene expression 
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and phenotype of cancer cells. For example, the H3K27me3 methyltransferase, EZH2, has been shown to 
be overexpressed in many cancers, including, prostate, breast, lung, bladder, and hepatocellular 
carcinoma (66-69). Moreover, a gain of function heterozygous missense mutation at Y641 of EZH2 has 
been detected in lymphoma and myeloid neoplasms (70). This mutation decreases the H3K27 
monomethylation, but increases the H3K27 trimethylation activity of EZH2 (71). In many cancer cell 
types, EZH2 increases migration, invasion and proliferation, and targets of H3K27me3 mediated 
silencing include the tumor suppressor genes, E cadherin, p21, and Runx3 (72-76).  
As an additional example of HMT deregulation in cancer, the mixed-lineage leukemia (MLL) 
family of H3K4 methyltransferases are commonly translocated and amplified in various leukemias 
(77,78).These genetic alterations to the MLL genes result in increased expression of many MLL target 
genes, including, HoxA7 and HoxA9, which are required for MLL-mediated transformation (79). 
Additionally, Ash2, which is an essential member of MLL complexes, has elevated protein levels in many 
cancers, and has been shown to be required for Ha-Ras-induced transformation of mouse embryonic 
fibroblasts (80).    
HDMs are also deregulated in many cancers. LSD1 is overexpressed in neuroblastoma, prostate 
and breast cancer (81,82,83), and its expression correlates with poor prognosis and reduced 
differentiation in neuroblastoma tumors (81). Importantly, LSD1 can act as a gene activator or repressor 
dependent on its H3K9me1/2 or H3K4me1/2 demethylase activity, respectively (84,85) 
The H3K4me2/3 specific- JARID family of jumonji demethylases have important roles as 
transcriptional repressors in many cancers (65,86,87). JARID1A has been found to contribute to cancer 
cell proliferation through the repression of the cyclin dependent kinase inhibitors, p16, p21 and p27 in 
gastric and cervical cancers (86). Knocking-down JARID1B in breast cancer cells induced senescence and 
resulted in the derepression of the tumor suppressor genes, BRCA1, HoxA5, and Let-7E (87). Seemingly 
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counterintuitive to role of the JARID family as H3K4 demethylases, JARID1B has been demonstrated to 
interact with the AR and activate the transcription of AR responsive genes (88). 
 The JMJD2 family of jumonji demethylases are overexpressed in many cancers (65,89). 
Members of this family possess H3K9me2/3 and H3K36me2/3 demethylase activity, and can act as 
transcriptional activators or repressors. In prostate and breast cancer, JMJD2 demethylases interact with 
the androgen receptor (AR) and estrogen receptor (ER) and are recruited to AR/ER responsive genes, 
where they act as transcriptional coactivators in a manner that is dependent on their H3K9me2/3 
demethylase activity (90-94). Some of the members of the JMJD2 family are discussed briefly below. 
JMJD2A is overexpressed in breast, prostate, colon, and bladder cancer, and has been shown to 
promote cancer cell proliferation (90,92,95,96). In fact, knocking-down JMJD2A inhibits proliferation in 
ER-positive and ER-negative breast cancer cell lines, as well as colon cancer cell lines (97,98,99).Because 
JMJD2A overexpression inhibits HP1 recruitment to heterochromatin, it is hypothesized that JMJD2A 
may increase cancer cell proliferation by antagonizing HP1 and promoting an open chromatin state 
during S-phase of the cell cycle, which would potentially aid in accelerated DNA replication (100).  
JMJD2B is overexpressed in both prostate and breast cancer (91,93). Unlike JMJD2A, modulating 
JMJD2B expression in breast cancer cells only alters the proliferation of ER-positive breast cancer cells, 
while the proliferation of ER-negative breast cancer cells remains unaffected (91,101). JMJD2B may also 
have a unique role in colorectal cancer and hypoxic response. While JMJD2 genes are all 
transcriptionally regulated by HIF-1α, as are many oxygen-dependent hydroxylases, the expression of 
JMJD2B is increased more substantially than the other JMJD2 members (102). It has also been 
demonstrated that by removing the H3K9me2/3 repressive mark from the promoters of hypoxia-
responsive genes, JMJD2B is critical for the increased expression of HIF-1α-regulated genes in response 
to hypoxia in colorectal cancer cells (102).    
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JMJD2C is overexpressed in prostate cancer, and the gene is amplified in esophageal carcinoma, 
B-cell lymphoma, Hodgkin lymphoma and breast cancer, which further supports its role as an oncogene 
(94, 103-105). Similar to the role of JMJD2B in colorectal cancer, JMJD2C has been shown to be a 
coactivator of HIF-1α in breast cancer (106). Furthermore, overexpressing JMJD2C led to mammosphere 
formation in nontransformed immortalized breast epithelial cells (105). Because mammosphere 
formation is a phenotype of cancer stem cells, and JMJD2C has been implicated in Oct4-mediated stem 
cell maintenance (107), these findings suggest that JMJD2C has a direct influence on tumorigenesis and 
cancer stem cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
The Roles of Histone Methyltransferases and Demethylases in Prostate Cancer 
Prostate cancer (PCa) is the most frequently diagnosed and the second leading cause of cancer 
related deaths in men (108). While most patients initially respond to androgen deprivation treatment, a 
significant percentage of patients relapse with currently untreatable castration resistant prostate cancer 
(CRPC) (109). During the progression to castration resistance (also referred to as androgen 
independence), PCa cells develop the ability to grow in androgen depleted conditions. The AR plays a 
vital role in prostate development and homeostasis, and the deregulation of the AR drives PCa 
tumorigenesis and progression (110). Delineating molecular mechanisms that contribute to AR activity 
may provide further insight into how aberrations in androgen signaling occur during the advancement of 
PCa, and may lead to the discovery of targets with prognostic and therapeutic value. 
AR is a steroid receptor that normally resides in the cytoplasm when not bound to its ligand. 
Upon interaction with androgens or androgen-like compounds, AR undergoes a conformational change, 
homodimerizes and translocates to the nucleus where it binds to androgen responsive elements (AREs) 
and regulates the transcription of target genes (110,111). AR recruits coregulators which modulate its 
transcriptional activity. Multiple HMTs and HDMs have been found to be overexpressed in prostate 
cancer, and these enzymes interact with AR and influence its transcriptional activity (112,113). 
Importantly, the modulation of AR coregulators is linked to sustained AR activity in androgen-depleted 
conditions, which contributes to the growth of CRPC cells (114), and the roles of HMTs and HDMs in 
CRPC are beginning to be brought to light. Upon being recruited to AR binding sites, histone modifying 
enzymes, including EZH2, NSD2, LSD1, and JMJD2 demethylases act as co-repressors and co-activators of 
the AR in a manner that is dependent on their methylation and demethylation activity (82,92-94,115-
117). The roles of specific HMTs and HDMs on AR activity and the development of CRPC are briefly 
discussed below. 
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The HMT EZH2 is overexpressed in PCa (66). Importantly, EZH2 has been shown to repress 
multiple tumor suppressor genes via H3K27me3, and increase cellular proliferation, migration and 
invasion (72). Interestingly, while it has been demonstrated that EZH2 can interact with AR and act as a 
transcriptional corepressor of certain AR target genes (116), a study carried out by Xu et al suggests that 
EZH2 changes roles in CRPC cells, and becomes a coactivator of AR (115). Upon being phosphorylated at 
serine 21 (S21), EZH2 methylates AR, and the EZH2/AR complex then activates the transcription of non-
canonical AR targets in CRPC cells (115). The phosphorylation of EZH2 at S21 is catalyzed by AKT, and 
inhibits the association of EZH2 with PRC2, thus abolishing the H3K27 methyltransferase activity of EZH2 
(115). Interestingly, AKT activity is higher in CRPC and H3K27me3 levels, although higher in PCa in 
comparison to benign cells, are reduced in CRPC (115,118). Furthermore, EZH2 levels and S21 
phosphorylated EZH2 have higher expression in CRPC, and the overexpression of EZH2 is sufficient to 
induce androgen independent (AI) growth in androgen dependent (AD) LNCaP PCa cells (115). Because 
of the coregulatory role of EZH2 on AR in CRPC, EZH2 inhibition should receive attention for future CRPC 
treatment possibilities. 
The precise catalytic activity of NSD2 has been elusive, as different studies have demonstrated 
that NSD2 possesses H3K36, H3K4, H3K27, and H4K20 methyltransferase activity (117,119-121). 
Regardless, NSD2 is overexpressed in PCa and acts as a transcriptional activator of AR in a manner that is 
dependent on its methyltransferase activity (117). In addition to being a transcriptional target of NF- κB 
signaling itself, NSD2 has been shown to be critical for the expression of NF- κB  regulated genes in CRPC 
cells (122). Interestingly, the regulatory role of NSD2 on NF- κB  target genes correlated with increases in 
activating marks, H3K36me2 and H3K36me3, at their respective promoters (122). Phenotypically, 
knocking-down NSD2 in CRPC cells decreased proliferation, increased apoptosis, and decreased tumor 
growth in mouse xenographs (122).While more research needs to be carried out on the roles of NSD2 in 
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PCa, present research indicates that NSD2 is involved in androgen and NF- κB signaling, which are both 
central to PCa development and progression.  
The HDM LSD1 was the first histone methyl modifying enzyme found to interact with AR and 
influence its transcriptional activity (85). Upon interacting with the AR, LSD1 can act as a coactivator or 
corepressor depending on the histone methyl mark targeted, H3K9me2/1 or H3K4me2/1 (85,123). 
Interestingly, AR, in partnership with LSD1, represses transcription of the AR gene itself when AR is 
ligand bound (123). Therefore, it is hypothesized that during androgen deprivation treatment, the lack 
of ligand causes derepression of AR transcription, contributing to increased AR expression and CRPC. 
LSD1 overexpression correlates with PCa relapse (82), and preliminary data suggests that inhibiting LSD1 
decreases the proliferation of CRPC cells (124). Therefore, LSD1 may be a viable therapeutic target for 
the treatment of CRPC. 
While LSD1 has H3K9me2 and H3K9me1 demethylating capabilities in complex with AR, LSD1 
does not have the ability to demethylate H3K9me3. However, as previously mentioned, AR interacts 
with JMJD2A, JMJD2B and JMJD2C, all of which have H3K9me3 demethylation activity and are 
overexpressed in PCa (92,93,94). In correlation with JMJD2 overexpression, H3K9me2 and H3K9me3 are 
both decreased with PCa progression (125). It has been demonstrated that AR can form a complex with 
LSD1 and JMJD2C, which cooperate for the sequential demethylation of H3K9me3, H3K9me2 and 
H3K9me1, thus facilitating an open chromatin state to allow for efficient AR binding and transcription 
activation of AR responsive genes (94). Although JMJD2A, 2B, and 2C all target the same histone marks 
for demethylation, the three enzymes do not seem to be redundant in their effect on AR. When the 
enzymes are overexpressed in PCa cells, only JMJD2C overexpression increases the PSA induction in 
response to androgens (94). Similarly, knocking-down JMJD2C in PCa cells decreases PSA induction in 
response to androgens (94); however, knocking-down JMJD2A in PCa cells reduces basal PSA levels, 
while androgen-induced PSA levels remain similar to the control cells (92). JMJD2B not only effects AR 
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activity, but also increases AR stability through deubiquitination of AR (93). Interestingly, JMJD2B is also 
an androgen responsive gene, thus forming a positive feedback loop with androgen signaling (93). Of 
particular interest in CRPC, JMJD2C expression is elevated in CRPC in comparison to AD PCa (126). 
Additionally, depleting JMJD2C levels in CRPC cells reduces both proliferation and the expression of 
genes known to be AR-regulated in CRPC (127). Therefore, while the inhibition of JMJD2A, 2B and 2C 
may all have therapeutic potential, the inhibition of JMJD2C may be of particular importance for CRPC 
treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Targeting Epigenetic Enzymes for Cancer Therapy 
Epigenetic enzymes are attractive targets for cancer therapy, because unlike DNA mutations, 
epigenetic marks are reversible. Therefore, investigating epigenetic alterations that contribute to cancer 
progression may have therapeutic value in cancer treatment. The DNMT inhibitor and hypomethylating 
agent, 5-azacytidine (5-AzaC), is often used in combination with other chemotherapeutic drugs in cancer 
therapy. While 5-AzaC derepresses many tumor suppressor genes that are silenced by promoter 
hypermethylation in cancer cells (128), the cytotoxicity of 5-AzaC is largely due to the DNA damage-
induced apoptosis that occurs in cancer cells as a result of further increased hypomethylation (129). It 
has been found that the combination treatment of 5-AzaC and TSA or vorinostat, HDAC inhibitors, 
synergistically induces apoptosis in many cancer cell types (130), and the combinatory treatment of 5-
AzaC and vorinostat is currently being investigated in clinical trials (131).  
HMTs and HDMs are also attractive targets for drug development and cancer therapy. 
Delineating the oncogenic role of EZH2 has led to the development of the EZH2 inhibitors, DZNeP and 
GSK126, which are currently being investigated for use in cancer therapeutics (132,133,134). 
Importantly, these inhibitors have been demonstrated to derepress various tumor suppressor genes 
which are targets of H3K27me3 mediated repression, as well as, to inhibit cancer cell proliferation and 
invasion (132,133,134). 
The oncogenic roles of various jumonji demethylases has led to an emphasis being placed on the 
development of jumonji demethylase inhibitors. Various inhibitors have been developed, including, α-
ketoglutarate mimics and iron chelators (135); however, these inhibitors have likely side effects, due to 
nonspecific inhibition of other important hydroxylases. Additionally, while numerous in vitro inhibitors 
have been developed, the development of cell permeable inhibitors with in vivo activity specific to 
jumonji demethylases has proved to be a challenge. Recently, a pan-jumonji demethylase inhibitor, JIB-
04, was discovered using an unbiased locus derepression assay (136). Importantly, JIB-04 did not inhibit 
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other hydroxylases tested, and selectively killed cancer cells in comparison to normal cells (136). 
Furthermore, because JIB-04 works in the sub-micromolar range, and was shown to inhibit tumor 
growth and increase survival in a mouse breast cancer model (136), it is possible that JIB-04 may be 
useful therapeutically. 
Because epigenetic modifications are reversible, and various epigenetic enzymes drive gene 
expression signatures that support malignant phenotypes of cancer cells, targeting epigenetic enzymes 
has proved, and will likely continue to prove, to be a fruitful endeavor for cancer therapy.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Delineating the Role of TMEFF2 in Prostate Cancer 
The transmembrane protein with epidermal-like growth factor domain and two follistatin 
domains (TMEFF2) is a glycoprotein that is expressed embryonically, and in the adult brain and prostate 
(137,138,139). A role for TMEFF2 in PCa was suggested by studies which found that TMEFF2 expression 
increases during PCa progression and androgen independence (140). The overexpression of TMEFF2 can 
potentially be explained by findings demonstrating that TMEFF2 expression is increased by the AR at the 
level of transcription and translation (141,142). Although overexpressed in PCa as an androgen 
responsive gene, the TMEFF2 promoter is highly methylated in many other cancer types, and multiple 
findings suggest that TMEFF2 phenotypically acts as a tumor suppressor (141, 143-149). Our lab has 
shown that TMEFF2 inhibits migration and invasion in PCa cells, and that this phenotype of TMEFF2 may 
be, at least in part, a result of its ability to modulate one carbon metabolism (143,144). We found that 
TMEFF2 interacts with sarcosine dehydrogenase (SARDH), an enzyme that catalyzes the reaction 
converting sarcosine to glycine while donating a methyl group to tetrahydrofolate (THF) to form 5,10 
methylene THF (143). Importantly, sarcosine levels has been demonstrated to have prognostic potential, 
as sarcosine increases with PCa progression, and sarcosine addition increases invasion in both PCa and 
benign prostate cells (150). Our lab has demonstrated that TMEFF2 overexpression, in nontransformed 
prostate epithelial cells, resulted in decreased sarcosine levels and a reduction in sarcosine induced 
invasion (143). While knocking-down TMEFF2 increased invasion of AI 22RV1 PCa cells, the TMEFF2 
knockdown cells displayed a significantly greater loss in invasion in response to methotrexate treatment 
when compared to control cells (144). Because methotrexate is a dihydrofolate reductase inhibitor 
which decreases THF generation from dihydrofolate (DHF), these results suggest that TMEFF2 modulates 
one carbon flux in prostate cancer cells (see figure 1 for one carbon metabolism schematic).  
 Based on its role in one carbon metabolism, we hypothesized that TMEFF2 influences 
epigenetic regulation in PCa cells. In order to test this hypothesis, we studied the effect of altering 
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TMEFF2 expression on the level of specific methyl histone marks. All of the methyl histone marks 
selected for this study have particular importance in PCa, either because the marks themselves are 
modulated during PCa progression, or because the expression of the enzymes that regulate the methyl 
marks are altered in PCa (see Table 1 for a list of selected methyl histone marks, and the enzymes that 
regulate the marks). Because of the importance of studying androgen independence for the progression 
of PCa therapy, we chose to use the C4-2B CRPC cell line for these studies. The C4-2B cell line is an AI 
derivative of the AD LNCaP cell line. Importantly, it has been demonstrated that the LNCaP/C4-2B model 
system shares similarities with the clinical progression from AD to AI PCa (151). In this study we 
demonstrate that knocking-down TMEFF2 with shRNA in C4-2B cells increases the level of H3K9me3, 
H3K9me2, and H3K36me3 in androgen depleted conditions, while the addition of dihydrotestosterone 
(DHT) abolishes this effect. Importantly, we also demonstrate that TMEFF2 expression levels correlate 
with changes in AI growth and resistance to the antigrowth effects of the pan-jumonji demethylase 
inhibitor, JIB-04. Because H3K9me3, H3K9me2 and H3K36me3 are methyl marks targeted by the JMJD2 
family of demethylases, these results indicate that TMEFF2 may work through one or multiple JMJD2 
enzymes to regulate histone methylation in C4-2B cells. Taken together our data demonstrate that 
TMEFF2 is a novel regulator of AI growth and epigenetic regulation in CRPC cells.  
 
 
 
 
 
 
 Table 1 
Table 1. Panel of methyl histone marks implicated in prostate cancer.
histone methyl marks selected for this study, the transcriptional effect of methyl marks, and the HMTs 
and HDMs that regulate the specific marks. Histone methyl marks that are dysregulated 
colored in blue, and HMTs and HDMs that are overexpressed
methyl histone marks deregulated in PCa: H3K9me3 and H3K9me2 (125), H3K27me3 (115,118), 
H3K4me3 (125). References for HMTs and HDMs overexpressed in PCa: JMJD2A (
JMJD2C (94), LSD1 (82), JARID1B (88), JARID1C (152), EZH2 (66), JMJD3 (153). 
 
 
 
 
 
 
 
 
 
 Above is a table showing the 
 in PCa are colored red. References for 
92), JMJD2B (93), 
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in PCa are 
  
Chapter 2: Material and Methods 
 
Cell culture 
The C4-2B cell line was purchased from ATCC, and maintained in RPMI media supplemented 
with 10% FBS, 100 units/ml penicillin, 100 mg/mL streptomycin, and Amphotericin B (LifeTechnologies). 
TMEFF2 was stably knocked-down in C4-2B cells using retroviral transduction with the pLKO.1 vector 
(Open biosystems) containing TMEFF2 targeted shRNA, with the pLKO.1 vector containing non-target 
shRNA being used for the scrambled control. TMEFF2 was stably over-expressed in the C4-2B from a 
CMV promoter within the pLenti vector (Invitrogen), which was transduced into C4-2B cells via lenti viral 
transduction; empty pLenti vector was transduced into C4-2B cells as a control. For DHT treatments, C4-
2B cells were grown in 10% CSS RPMI for 24 hours, at which time, cells were treated with 10% CSS RPMI 
with either 10 nM DHT or .0001% EtOH for –DHT vehicle control. Cells were then grown in 10 nM DHT or 
.0001% EtOH for 24 hours before being harvested.  
 
Protein extraction and western blot analysis 
For protein extraction, cultured cells were trypsinized, pelleted, and washed twice in PBS. 
Pelleted cells were then either lysed in Pierce RIPA buffer with protease inhibitor cocktail (Sigma) for 
whole cell lysate, or Triton extraction buffer (TEB) containing .5% Triton X 100, 2 mM PMSF, .02% 
sodium azide in PBS for histone acid extraction. RIPA lysate was then centrifuged at 14,000xg for 15 
minutes at 4
o
C, and supernatant containing protein was then aliquoted and stored at -80
o
C. ABCAM 
histone acid extraction protocol was used for histone extraction. Briefly, after lysis with TEB, nuclei were 
pelleted via centrifugation at 6,500xg for 10 minutes at 4
o
C. Nuclei pellets were then washed in TEB, and 
pelleted again using the same centrifugation conditions. Pelleted nuclei were then lysed in .2 N HCl, and 
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incubated overnight at 4
o
C. Lysates were then centrifuged at 6,500xg for 10 minutes at 4
o
C, supernatant 
containing histones was then aliquoted and stored at -80
o
C.  
For western blot analysis, protein lysates (20 ug whole cell lyate, 10 ug acid extract) were 
separated in 4% to 20% gradient gels, and transferred to nitrocellulose membranes (Biorad). 
Membranes were blocked in TBS-T (Tris buffered saline with .01% Tween 20) with 5% NFDM for 1hour at 
room temperature. Membranes were incubated in the following primary antibodies in 5% NFDM TBS-T 
either overnight at 4
o
C or 1 hour at room temperature: H3K27me3 (Millipore 07-449, 1:7000), H3K9me3 
(Millipore 07-442, 1:500), H3K9me2 (Millipore 07-441, 1:500), H3K9me1 (Abcam 9045, 1:6000), 
H3K4me3 (Millipore 07-473, 1:2500), H3K36me3 (Abcam 9050, 1:2000), H4 (Abcam 10158, 1:5000), 
JMJD2B (Bethyl labs A301-478A, 1:2000), JMJD2A (Bethyl labs A300-861A, 1:2000), JMJD2C (Bethyl labs 
A300-885A, 1:2000), AR (Santa Cruz 441, 1:1000), TMEFF2 (SDIX, 1:1000), Calnexin (Abcam 22595, 
1:2000). Goat anti-rabbit hrp-conjugated secondary antibodies were used at 1:10,000 in .5% NFDM TBS-
T (Santa Cruz Biotechnologies). All washes were conducted in TBS-T, and SuperSignal West Pico 
Chemiliminescent Substrate was used for protein detection (Thermo Scientific). Image J program was 
used for western blot quantification. 
 
Growth analysis 
 For MTT assays, cells grown in 96 well plates were incubated for 3 hours in 100 μl of phenol red 
free RPMI, supplemented with MTT (.5mg/ml; Sigma) and 1% FBS. Following 3 hour incubation, 250μl of 
DMSO per well was added to solubilize crystals formed from MTT treatment. Absorbance was then read 
at 550 nm wavelength. 
For analyzing C4-2B cell growth in the presence and absence of DHT, cells were hormone 
starved in 10% CSS RPMI for 24 hours, before being trypsinized and seeded in 96 well plates at a density 
of 8,000 cells per well. After allowing 24 hours for cell attachment in 10% CSS RPMI, one plate of cells 
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was subjected to MTT assay to establish a time zero, while cells on remaining plates were treated with 
10 nM DHT or .0001% EtOH vehicle control, and allowed to grow for 72 hours, before being analyzed by 
MTT assay. Growth was analyzed as the change in absorbance obtained from the untreated time zero 
plate to the absorbance obtained from plate 72 hours after treatment. 
For analyzing C4-2B cell growth in the presence and absence of DHT and in the presence and 
absence of AR siRNA, cells were hormone starved and seeded in 96 well plates as previously described. 
After allowing 24 hours for attachment in 10% CSS RPMI, cells were transfected with siRNA either 
targeting AR (Thermo Scientific Dharmacon L-003400-00) or with non-target control siRNA (Thermo 
Scientific Dharmacon D-001206-14-05). The Thermo Scientific DharmaFECT protocol was followed for 
the transfections, using 25nM siRNA and .1% DharmFECT reagent #3. Transfections were allowed to 
proceed for 48 hours, to allow for efficient AR knockdown before subsequent treatments. After 48 hour 
transfection, one plate was subjected to MTT assay to provide a time zero reading before DHT 
treatment. In remaining plates, the transfection media was replaced with 10% CSS RPMI media, 
supplemented with either 10 nM DHT or .0001% EtOH vehicle control. Cells were then grown for 72 
hours, before being evaluated by MTT assay. Growth was analyzed as the change in absorbance 
obtained from the untreated time zero plate to the absorbance obtained from plate 72 hours after 
treatment. For analyzing AR knockdown efficiency, cells were seeded in 6 well plates, and AR knock-
down and DHT treatments were carried out as described for growth analysis. Cells were harvested for 
protein extraction 24 hours after DHT treatment, and AR knock-down efficiency was analyzed by 
western blot.  
For analyzing C4-2B cell growth in response to JIB-04 (prepared in DMSO) in the presence and 
absence of DHT, cells were hormone starved and seeded in 96 well plates as previously described. After 
allowing 24 hours for attachment in 10% CSS RPMI, one plate was subjected to MTT assay to provide a 
time zero growth reading, and remaining cells were split into four different treatments: JIB-04(Sigma 
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SML0808) and 10 nM DHT, .0025% DMSO (JIB-04 vehicle) and 10 nM DHT, JIB-04 and .0001% EtOH (DHT 
vehicle), or .0025% DMSO (JIB-04 vehicle) and .0001% EtOH (DHT vehicle). JIB-04 concentrations ranged 
from .05 μM to .5 μM, and all concentrations of JIB-04 contained a total of .0025% DMSO. Cells were 
then grown for 72 hours, before being analyzed by MTT assay. Growth was analyzed as the change in 
absorbance obtained from the untreated time zero plate to the absorbance obtained from plate 72 
hours after treatment.  
 
Statistical analysis 
Data are presented as mean -/+ SD. Differences were analyzed using paired t-tests. Two-tail 
paired t-tests were used unless otherwise indicated. p<.05 was considered significant, while p<.1 was 
considered trending towards significance in some data presented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 3: Results 
 
TMEFF2 modulates JMJD2 controlled methyl histone marks in androgen depleted conditions 
 We have previously demonstrated that TMEFF2 is a modulator of one carbon metabolism in PCa 
cells (). Because changes in one carbon metabolism can alter the activity of DNA and histone 
methyltransferases and demethylases, we hypothesized that TMEFF2 regulates epigenetic processes in 
PCa cells. To begin testing this hypothesis, we determined the effect of silencing TMEFF2 on specific 
methyl histone marks. TMEFF2 was stably knocked-down in C4-2B cells using shRNA (C4-2B sh_TMF2) 
(fig 2A), and the levels of selected methyl histone marks were measured via western blot analysis. 
Because HMTs and HDMs are involved in androgen signaling, we also treated the cells with 10nM DHT, 
or with EtOH as vehicle control. We investigated a panel of six methyl histone marks based on their 
relevance in PCa; four of the marks are deregulated in PCa, and all six marks are regulated by enzymes 
that are overexpressed in PCa (table 1). In androgen depleted conditions (-DHT), TMEFF2 silencing 
resulted in an approximate two-fold increase in H3K9me3 and H3K9me2 levels (p<0.05), and an 
approximate 50% increase in H3K36me3 (p=0.08), with respect to the sh_scramble negative control (C4-
2B sh_scramble) (fig 2B & 2C); however, in each case, the addition of DHT abolished or reduced the 
effect of silencing TMEFF2 on the levels of these methyl histone marks. In fact, DHT treatment 
decreased H3K9me3 levels in C4-2B sh_TMF2 cells to the level of C4-2B sh_scrambled - which displayed 
similar levels of H3K9me3 in the presence and absence of DHT. While DHT addition did not result in 
significant changes in H3K9me2 levels, sh_scrambled cells demonstrated an approximate 50% increase 
in H3K9me2 with DHT addition (p=0.06), thus contributing to the lack of difference seen in H3K9me2 
between sh_scrambled and sh_TMF2 cells in the presence of DHT. Importantly, neither H3K4me3 nor 
H3K27me3 displayed change in the presence or absence of DHT in response to TMEFF2 KD, indicating 
specificity in the methyl histone marks modulated by TMEFF2. Interestingly, the histone methyl marks 
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that presented increases in response to TMEFF2 KD in androgen depleted conditions, H3K9me3, 
H3K9me2, and H3K36me3, are all methyl marks regulated by the JMJD2 family of demethylases, 
suggesting that TMEFF2 may work through one or multiple JMJD2 demethylases to modulate histone 
methylation.  
We then tested whether TMEFF2 modulates the expression of any of the three JMJD2 
demethylases known to be overexpressed in PCa, JMJD2A, JMJD2B and JMJD2C, which could account for 
the increase in methyl mark observed in response to TMEFF2 silencing (fig 2D,2E). Surprisingly, while not 
statistically significant, both JMJD2B and JMJD2C showed trends toward increased protein expression in 
sh_TMF2 cells grown in the absence of DHT, when compared to the sh_scrambled control. JMJD2A 
expression was not changed significantly by TMEFF2 silencing or DHT addition. JMJD2B protein 
expression was androgen responsive, as previously demonstrated (93), and had equal expression in 
sh_scrambled and sh_TMF2 cells in the presence of DHT. All together these results indicate that while 
JMJD2 regulated methyl histone marks are elevated in sh_TMF2 cells grown in the absence of DHT, the 
expression levels of the JMJD2 demethylases do not correlate with this observation, suggesting that 
TMEFF2 may affect the JMJD2 demethylase activity.   
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Figure 2. Knocking-down TMEFF2 increases JMJD2 regulated methyl histone marks in the absence of 
DHT. A: Western blot analysis of whole cell lysate demonstrating TMEFF2 knockdown in C4-2B sh_TMF2 
cells in the presence and absence of DHT. The red arrow indicates the TMEFF2 band. Calnexin was used 
as a loading control. B: Representative methyl histone western blots from histone acid extracts, 
demonstrating the methylation of specific histone lysine residues in C4-2B sh_scrambled and C4-2B 
sh_TMF2 cells grown in the presence and absence of DHT. H4 was used as a loading control. C: Graphical 
representation of the average levels of methyl histone marks in C4-2B sh_scrambled and C4-2B 
sh_TMF2 cells grown in the presence and absence of DHT, as quantified from western blot analysis. 
Averages and statistics were calculated from 3 or 4 independent repeats. * indicates p<0.1, ** p<0.05, 
*** p<0.02. D: Representative western blots from whole cell lysate, demonstrating JMJD2A, JMJD2B, 
and JMJD2C expression in C4-2B sh_scrambled and C4-2B sh_TMF2 cells grown in the presence and 
absence of DHT. Calnexin was used as a loading control. E: Graphical representation of the average 
levels of JMJD2A, JMJD2B, and JMJD2C protein expression in C4-2B sh_scrambled and C4-2B sh_TMF2 
cells grown in the presence and absence of DHT, as quantified from western blot analysis. Averages and 
statistics were calculated from 3 independent repeats.    
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TMEFF2 increases androgen independent growth and AR activity 
 
 The results presented indicate that TMEFF2 modulates histone methyl marks levels by affecting 
the activity of JMJD2 demethylases. Since the JMJD2 enzymes increase growth in many cancer cell types, 
we hypothesized that TMEFF2 can modulate growth in C4-2B cells by influencing JMJD2 activity. To 
begin testing this hypothesis, we used MTT analysis to measure C4-2B cell growth in response to both, 
silencing and overexpressing TMEFF2, in the presence and absence of DHT (fig 3B & 3C). TMEFF2 
overexpression was achieved by stably transducing C4-2B cells with a pLenti vector, which expressed 
TMEFF2 from a CMV promoter (fig 3A). The results indicated that DHT addition significantly increased 
growth in all C4-2B cells tested; indicating that while the C4-2B cell line has the ability to grow in 
androgen depleted conditions, C4-2B cell growth is responsive to androgens (fig 3B & 3C). Neither 
silencing nor overexpressing TMEFF2 significantly affected androgen induced growth in C4-2B cells. 
Conversely, in the absence of DHT, TMEFF2 overexpressing cells (C4-2B TMF2), but not TMEFF2 silenced 
cells, displayed a significant increase in growth in comparison to the empty vector control cells (C4-2B 
EV).These results demonstrate that TMEFF2 overexpression increases androgen independent growth in 
C4-2B cells.  
Since ligand-independent AR activity is an important mechanism for androgen independent 
growth in many AR positive CRPC cell lines, we wanted to determine whether the increase in androgen 
independent growth conferred by TMEFF2 overexpression in C4-2B cells is dependent on AR. To 
investigate the role of AR in TMEFF2 mediated growth, we transiently knocked-down AR with siRNA in 
C4-2B EV and C4-2B TMF2 cells and measured cell growth in the presence and absence of androgens (fig 
4A). Western blot analysis demonstrates that AR KD efficiency was approximately 90% at the level of 
protein expression, and was similar in both C4-2B EV and C4-2B TMF2 cells (fig 4B). Furthermore, AR KD 
dramatically reduced TMEFF2 expression in the presence of DHT in C4-2B EV and C4-2B TMF2 cells (fig 
4B). As expected, AR KD completely abolished DHT-induced growth in C4-2B EV cells to the level 
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observed in the absence of DHT. Significantly, however, TMEFF2 overexpressing cells demonstrated a 
30% increase in DHT-induced growth even when the AR was KD. Moreover, AR KD did not abolish the 
increase in androgen independent growth conferred by TMEFF2 overexpression. These results indicate 
that TMEFF2 regulates growth independent of AR in the absence of androgens and also increases 
androgen-induced growth when AR levels are depleted; thus indicating that TMEFF2 modulates growth 
both dependently and independently of AR in the presence and absence of ligand, respectively. 
Importantly, while TMEFF2 expression from the CMV promoter in C4-2B TMF2 cells is responsive to 
androgens (fig 3A), AR KD inhibited TMEFF2 induction in response to DHT (fig 4B); therefore, the 
increase in growth in the AR KD C4-2B TMF2 cells grown in the presence of DHT is not a result of 
increased TMEFF2 expression. Furthermore, because AR protein expression is not increased by TMEFF2 
overexpression (fig 4B), these results indicate that TMEFF2 may be an effector of AR activity.  
In order to test whether TMEFF2 modulates AR activity, we measured PSA protein levels in C4-
2B EV/TMF2 and C4-2B sh_scrambled/sh_TMF2 cells grown in the presence and absence of DHT (fig 5). 
While silencing TMEFF2 decreased PSA levels in the absence and presence of DHT, overexpressing 
TMEFF2 only increased the induction of PSA with the addition of DHT. Importantly, because neither 
silencing nor overexpressing TMEFF2 altered AR protein expression in the presence or absence of DHT, 
these data indicate that TMEFF2 is a coactivator of AR mediated transcription.   
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Figure 3. TMEFF2 overexpression increases androgen independent growth in C4
blot analysis of whole cell lysate demonstrating TMEFF2 overexpression in C4
induction in the presence of DHT. The red arrow indicates the TMEFF2 band.
loading control. B: Cell growth of C4
and absence of DHT. Growth was calculated relative to the growth of C4
with each repeat consisting of an average of 6 replicates for each condition
growth of C4-2B EV and C4-2B TMF2 cells grown in the presence and absence of DHT. Growth was 
calculated relative to the growth of C4
replicates for each condition; ** indicates p<
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Figure 4. TMEFF2 increases growth independent of AR in the absence of DHT, and increases androgen-
regulated growth in presence of DHT when AR levels are depleted. A: Cell growth of C4-2B EV and C4-
2B TMF2 cells grown in the presence and absence of DHT, and the presence and absence of AR KD. siAR 
designates cell growth in the presence of AR siRNA, while sicon designates cell growth in the presence of 
the non-target siRNA control. Growth was calculated as fold of EV –DHT sicon. n=3, with each repeat 
consisting of an average of 6 replicates for each condition; ** indicates p<0.05, *** indicates p<0.02. 
One tail t-tests were used for statistical comparisons between sicon –DHT and sicon +DHT, while two-tail 
t-tests were used for other statistical comparisons. B: Western blot analysis demonstrating AR KD 
efficiency and TMEFF2 expression in response to AR KD in the presence and absence of DHT. Red arrow 
indicates full length AR, while remaining bands designated within the orange bracket indicate splice 
isoforms of AR. 
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Figure 5. TMEFF2 positively regulates PSA expression without modulating AR protein levels
Representative western blots from whole cell lysate, demonstrating AR and PSA expression in C4
sh_scrambled and C4-2B sh_TMF2 cells grown in the presence and a
as a loading control. B: Representative western blots from whole cell lysate, demonstrating AR and PSA 
expression in C4-2B EV and C4-2B TMF2 cells grown in the presence and absence of DHT. Calnexin was 
used as a loading control.    
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TMEFF2 and androgens confer resistance to the anti-growth effects of JIB-04 
 
 
 Since TMEFF2 decreases JMJD2 controlled methyl histone marks and increases growth in 
androgen depleted conditions, we wanted to determine whether these two effects of TMEFF2 are 
mechanistically linked and therefore whether TMEFF2 modulates androgen independent growth by 
influencing JMJD2 activity. In order to address this, we measured the effect of TMEFF2 on growth in 
response to JIB-04, a pan-jumonji demethylase inhibitor. TMEFF2 overexpressing or EV control cells 
were grown in the presence or absence of JIB-04 and DHT and the effect on growth was determined 
using an MTT assay. In order to measure growth sensitivity to JIB-04, growth was measured relative to 
the DMSO vehicle control for each of the four conditions, C4-2B EV -/+DHT and C4-2B TMF2 -/+DHT. 
While JIB-04 addition negatively affected growth in all cell lines/conditions tested, the addition of DHT 
improved relative growth in response to JIB-04, in both EV and TMEFF2 overexpressing cells (fig 6A). 
Furthermore, C4-2B TMF2 cells demonstrated increased relative growth when compared to C4-2B EV 
cells in response to JIB-04, in both the presence and absence of DHT. These results indicate that 
androgens and/or TMEFF2 confer resistance to the anti-growth effect of JIB-04. Interestingly, C4-2B 
TMF2 cells grown in the absence of DHT showed almost identical relative growth to C4-2B EV cells 
grown in the presence of DHT, at each JIB-04 concentration measured. This result suggests that 
overexpressing TMEFF2 and increasing androgen signaling have a similar effect on jumonji demethylase 
activity.  
 In order to statistically analyze the growth inhibitory effect of JIB-04, the GI50, or the drug 
concentration that results in 50% growth inhibition, was calculated for C4-2B EV and C4-2B TMF2 grown 
in the presence and absence of DHT (fig 6B). The addition of DHT significantly increased the GI50 from .1 
μM to .19 μM for the C4-2B EV cells and from .18 μM to .35 μM for the C4-2B TMF2 cells. Importantly, 
because in the absence of JIB-04, C4-2B EV cells have increased growth in the presence of DHT when 
compared to C4-2B TMF2 cells grown in the absence of DHT (fig 3C), the increased resistance to JIB-04 
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demonstrated by the TMEFF2 overexpressing cells cannot be solely accounted for by differences in basal 
growth. Additionally, when grown in the presence of DHT, C4-2B TMF2 cells demonstrated increased 
resistance to JIB-04, compared C4-2B EV cells (fig 6A & 6B), while the growth of C4-2B TMF2 was similar 
to C4-2B EV in the presence of DHT (fig 3C); these results further indicate that TMEFF2 confers 
resistance to JIB-04 independent of modulating basal growth. These results demonstrate that both 
TMEFF2 and androgens confer resistance to JIB-04, at least partially, independent of basal cell growth; 
thus indicating that both TMEFF2 and androgens may increase jumonji demethylase activity in C4-2B 
cells. Because TMEFF2 and androgen signaling are coregulated, it is difficult to suggest whether a 
synergistic effect is present when TMEFF2 is overexpressed and androgens are added. Therefore, it is 
difficult to speculate whether TMEFF2 and androgen signaling act on the jumonji demethylases through 
a similar or independent mechanism.  
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Figure 6. TMEFF2 and androgens confer resistance to the anti-growth effects of JIB-04. A: Cell growth 
at each concentration of JIB-04 is presented as percent growth of cells grown in the presence of the 
DMSO vehicle, for C4-2B EV and C4-2B TMF2 grown in the presence and absence of androgens. The 
growth inhibition curve was constructed using the average percent growth of four independent repeats, 
with each repeat consisting of four replicates at each concentration and condition. B: Graphical 
representation of the average GI50 for JIB-04 in C4-2B EV and C4-2B TMF2 grown in the presence and 
absence of DHT. The GI50’s were calculated from the growth inhibition curve generated from each 
individual repeat. n=4; ** indicates p<0.05, *** p<0.02. 
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Chapter 4: Discussion 
 We have previously demonstrated that TMEFF2 modulates one carbon metabolism, and 
suppresses migration and invasion in PCa cells (143,144). Because alterations in flux within one carbon 
metabolism can affect epigenetic processes by potentially modifying the activity of methyltransferases 
and/or demethylases, we investigated the ability of TMEFF2 to influence PCa cell epigenetics. In this 
study we demonstrated that silencing TMEFF2 increases H3K9me3, H3K9me2 and H3K36me3 histone 
levels in androgen independent C4-2B PCa cells grown in androgen depleted conditions (fig 2B & 2C). 
The increase is possibly a result of decreased activity of one or more JMJD2 enzymes (since the JMJD2 
family has H3K9me2/3 and H3K36me2/3 demethylase activity) through silencing TMEFF2. Interestingly, 
the addition of DHT abrogated the effect of silencing TMEFF2 on these histone methyl marks, which can 
be potentially explained by a few different mechanisms: 1) TMEFF2 may work partially through AR to 
modulate JMJD2 activity, and the addition of DHT and androgen signaling may compensate for the 
silencing of TMEFF2 in C4-2B sh_TMF2 cells. In fact, we have also demonstrated that TMEFF2 increases 
AR activity (fig 5A & 5B). 2) Since JMJD2B is an androgen responsive gene, it is possible that with the 
addition of DHT, JMJD2B expression rises to a sufficient level to compensate for the increase in JMJD2 
controlled marks caused by silencing TMEFF2. However, this mechanism is unlikely, as silencing TMEFF2 
results in a tendency towards increased basal expression of JMJD2B and JMJD2C in the absence of DHT 
(fig 2D,2E), while JMJD2 controlled marks are elevated with respect to the sh_scrambled control. 3) 
Because TMEFF2 is androgen responsive at the level of transcription and translation, TMEFF2 protein 
levels may rise enough to abolish the effect of silencing TMEFF2 when C4-2B sh_TMF2 cells are grown in 
the presence of DHT. However, TMEFF2 levels rise significantly in sh_scrambled cells with addition of 
DHT, while JMJD2 controlled methyl histone marks are not significantly modulated by DHT in these cells 
(fig 2A,2B,2C). Therefore, interplay between AR and TMEFF2 in modulating JMJD2 controlled methyl 
histone marks appears to be the most favorable potential mechanism.   
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 While silencing TMEFF2 increased JMJD2 controlled marks in androgen depleted conditions, 
JMJD2B and JMJD2C protein levels demonstrated trends toward higher expression in C4-2B sh_TMF2 
cells when compared to their levels in C4-2B sh_scrambled cells grown in the absence of DHT (fig 2D,2E). 
These results indicate that TMEFF2 may increase JMJD2 activity. Importantly, HIF-1α has been 
demonstrated to increase the transcription of certain JMJD2 genes under conditions of compromised 
JMJD2 activity, such as, hypoxia or oxidative stress. Therefore, by modulating one carbon metabolism 
and potentially the cellular redox state, silencing TMEFF2 could simultaneously decrease the activity and 
increase the expression of JMJD2 enzymes; however, the net effect of such regulation on global histone 
methylation is extremely complicated and difficult to predict. Nevertheless, because TMEFF2 decreases 
JMJD2 controlled methyl histone marks in androgen depleted conditions, our data indicate that TMEFF2 
is a novel epigenetic modulator in CRPC. 
 In correlation with the role of JMJD2 enzymes as positive growth regulators in PCa cells, we 
demonstrated that TMEFF2 overexpression increases androgen independent growth in C4-2B cells (fig 
3C). Importantly, TMEFF2 overexpression increased C4-2B resistance to the anti-growth activity of JIB-
04, a pan-jumonji  demethylase inhibitor, in the presence and absence of DHT(fig 6A & 6B); thus 
suggesting that the effect of TMEFF2 on methyl histone marks and cell growth are somewhat linked. 
Along with being an effector of JMJD2 regulated methyl histone marks and growth in androgen depleted 
conditions, we demonstrated that TMEFF2 also increases androgen induced growth in C4-2B cells when 
AR levels are depleted (fig 4A). Since this result indicates that TMEFF2 modulates AR activity, we tested 
the effect of both silencing and overexpressing TMEFF2 on PSA levels in C4-2B cells grown in the 
presence and absence of DHT (fig 5A & 5B). In both cases PSA induction in response to DHT positively 
correlated with TMEFF2 expression. Furthermore, silencing TMEFF2 drastically reduced PSA levels in 
androgen depleted conditions, while overexpressing TMEFF2 did not alter PSA expression in the absence 
of DHT. Taken together, our results indicate that TMEFF2 promotes androgen independent growth, and 
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increases JMJD2 and AR activity in C4-2B cells, suggesting that TMEFF2 has an oncogenic role in CRPC, 
mediated by its effect on AR and JMJD2 activity.   
 Several studies have demonstrated that TMEFF2 acts as a tumor suppressor in gastric cancer 
(149), and the TMEFF2 promoter is hypermethylated in multiple cancers (146,147). In fact, our lab has 
demonstrated that TMEFF2 inhibits migration and invasion in PCa cells (143,144,148). However, the role 
of TMEFF2 in PCa has been perplexing, as TMEFF2 expression has been found to increase during PCa 
progression and in CRPC (140), which suggests an oncogenic role of TMEFF2 in PCa. It is possible that the 
biological function of TMEFF2 is regulated, so that it initially signals as a tumor suppressor, while its 
oncogenic roles are dependent on more advanced stages of PCa. In correlation with increased 
expression in CRPC, we demonstrate in this study that TMEFF2 is a novel modulator of androgen 
independent growth in C4-2B cells. Importantly, during the progression to CRPC, PCa cells obtain means 
to maintain AR activity in androgen depleted conditions and/or become more reliant on other pathways 
for growth (114). The data presented here indicate that while TMEFF2 influences AR activity, it may 
increase androgen independent growth through increasing JMJD2 activity, which in turn can increase 
cell growth dependently and independently of the AR, as JMJD2 enzymes are known activators of AR. 
Therefore we propose that not only does AR regulate TMEFF2 expression, but that the role of TMEFF2 in 
PCa involves both its influence on JMJD2 and AR activity, and thereby CRPC growth (see fig 7 for 
proposed model). 
 Importantly, it has been demonstrated that the extracellular ectodomain of TMEFF2 can be 
cleaved via an ADAM17/γsecretase mechanism, and our lab and other studies have shown that the 
soluble ectodomain has a pro-growth function (143,154). It is therefore possible that by expressing a 
high amount of proteases, C4-2B cells may cleave TMEFF2 in an efficient manner, so that the oncogenic 
soluble ectodomain is increased significantly when TMEFF2 is overexpressed in this cell line. 
Importantly, protease cascades have been shown to increase with the progression of PCa in the TRAMP 
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mouse PCa model (155). It is also possible that DHT addition stimulates cleavage of TMEFF2 and 
ectodomain release, as it has been observed for other transmembrane proteins (156), contributing to its 
growth promoting effect. Indeed, it is possible that the TMEFF2 soluble ectodomain is required for both 
the epigenetic and growth phenotypes observed in the C4-2B cell line. In future experiments, the 
soluble ectodomain will be overexpressed in C4-2B cells, and it can be determined how the growth 
effect of TMEFF2 ectodomain overexpression compares to full-length TMEFF2 overexpression in C4-2B 
cells. Additionally, TMEFF2 cleavage in cell media can be quantified via western blot analysis.  
 Importantly, because TMEFF2 increases PCa growth in androgen depleted conditions and when 
AR protein levels are depleted, it is possible that TMEFF2 overexpression may contribute to PCa 
resistance to anti-androgen or potential AR silencing treatments. Because developed resistance to anti-
androgens is a key process for CRPC relapse, TMEFF2 overexpression may contribute to progression of 
PCa to CRPC. Furthermore, its potential role with AR and JMJD2 demethylases may make TMEFF2 
relevant in future CRPC therapeutics.   
 Future experiments will be directed at further delineating the molecular mechanisms through 
which TMEFF2 increases CRPC growth. We will be conducting Chip-seq analysis with AR and H3K9me3 in 
C4-2B sh_scrambled and sh_TMF2 cells grown in the presence and absence of DHT. Importantly, the 
Chip-seq analysis will be partnered with microarray analysis, so that targets of TMEFF2 mediated 
through its effect on AR and/or H3K9me3 can be identified. Furthermore, microarray analysis with C4-
2B EV and C4-2B TMF2 cells grown in the presence and absence of androgens, will provide potential 
targets of TMEFF2 that may be involved in its pro-growth phenotype. Additionally, the experiments 
mentioned above will be carried out in LNCaP cells, in which TMEFF2 is silenced by shRNA. These 
experiments will aid in determining whether TMEFF2 changes roles during the progression of PCa from 
AD to CRPC, and its therapeutic potential alone or in combination with anti-androgens or other AR-
targeted treatments.    
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Figure 7. A proposed model for the role of TMEFF2 in CRPC growth, through modulating JMJD2 and AR 
activity.  
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